Taysha Gene Therapies, Inc. TSHA Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$109M-22.1% | -$89.3M— | —— | -$166.01M+4.9% | ||
| $1.08M-12.0% | $1.23M-12.0% | $1.4M+14.3% | $1.22M+132% | ||
| $13.3M+1.5% | $13.1M+65.8% | $7.91M-56.2% | $18.04M-0.8% | ||
| -$93.09M-14.6% | -$81.23M-11.2% | -$73.02M— | —— | ||
| $738K+96.3% | $376K— | —— | $20.62M+34.7% | ||
| —— | -$376K+94.9% | -$7.4M+70.3% | -$24.93M-15.7% | ||
| $274.59M+256% | $77.04M-45.2% | $140.64M+169% | $52.2M— | ||
| $196.31M+4,103% | -$4.9M— | —— | —— | ||
| -$93.83M-15.0% | -$81.6M-6.1% | -$76.89M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Taysha Gene Therapies, Inc.'s cash flow data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.